source
- Scribe Therapeutics raises $129 million in rare early-stage IPO to fund epigenetic heart disease therapyScribe Therapeutics, founded by Jennifer Doudna, completed an IPO raising nearly $129 million, selling 8.58 million shares at $15 each. It is the first gene‑editing company to go public in more tha…
- FDA panel backs compounding of epitalon, rejects emideltide in narrow voteThe FDA advisory committee voted to allow compounding pharmacies to produce the peptide epitalon, while narrowly voting against allowing the production of emideltide. The decision follows the pane…